<DOC>
	<DOC>NCT01156077</DOC>
	<brief_summary>This is an open-label, multi-center, two-part, parallel-design study to assess the PK, safety, and tolerability of TR-701 FA and its active metabolite, TR-700, following a single oral dose (Part A) or IV dose (Part B) of TR-701 FA in 12 to 17 year old adolescent patients.</brief_summary>
	<brief_title>Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>males and females, between 12 and 17 years of age, inclusive; receiving prophylaxis for or have a confirmed or suspected infection with Gram positive bacteria and receiving concurrent antibiotic treatment with Gram positive antibacterial activity in stable condition females must be premenarchal, surgically sterile, abstinent, or practicing an effective method of birth control males will either be surgically sterile, abstinent, or practicing an effective method of birth control relevant history of seizures, clinically significant cardiac arrhythmia, cystic fibrosis, moderate or severe renal impairment, or any physical condition that could interfere with the interpretation of the study results any acute or chronic condition that, in the opinion of the Investigator, would limit the patient's ability to complete and/or participate in this clinical study physiciandiagnosed migraine headaches history of infection with hepatitis or other significant hepatic disease females who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>antibiotic</keyword>
	<keyword>Adolescents receiving antibiotics</keyword>
</DOC>